123 related articles for article (PubMed ID: 28216900)
1.
Jeong SJ; Choi JY; Dong MS; Seo CS; Shin HK
Pharmacogn Mag; 2017; 13(49):153-158. PubMed ID: 28216900
[TBL] [Abstract][Full Text] [Related]
2. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
3. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
Kim HJ; Park YI; Dong MS
Toxicol In Vitro; 2006 Oct; 20(7):1159-67. PubMed ID: 16621434
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
Alexander B; Fishman AI; Green D; Choudhury MS; Konno S
Urol Oncol; 2013 Jan; 31(1):104-9. PubMed ID: 21795077
[TBL] [Abstract][Full Text] [Related]
5. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
Dai J; Shen R; Sumitomo M; Stahl R; Navarro D; Gershengorn MC; Nanus DM
Clin Cancer Res; 2002 Jul; 8(7):2399-405. PubMed ID: 12114445
[TBL] [Abstract][Full Text] [Related]
7. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
Diao X; Chen X; Pi Y; Zhang Y; Wang F; Liu P; Gao Y; Wang X; Yang S; Lu S
Oncol Rep; 2018 Aug; 40(2):1174-1184. PubMed ID: 29917167
[TBL] [Abstract][Full Text] [Related]
9. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
10. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
11. PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells.
Ikezoe T; Chen SS; Yang Y; Heber D; Taguchi H; Koeffler HP
Int J Oncol; 2003 Nov; 23(5):1461-70. PubMed ID: 14532991
[TBL] [Abstract][Full Text] [Related]
12. Development and pre-validation of an in vitro transactivation assay for detection of (anti)androgenic potential compounds using 22Rv1/MMTV cells.
Sun S; Park EJ; Choi YH; Lee HS; Ahn BY; Dong MS
Reprod Toxicol; 2016 Apr; 60():156-66. PubMed ID: 26867867
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes.
Hartel A; Didier A; Ulbrich SE; Wierer M; Meyer HH
J Steroid Biochem Mol Biol; 2004 Oct; 92(3):187-97. PubMed ID: 15555912
[TBL] [Abstract][Full Text] [Related]
16. Kaempferol inhibits benign prostatic hyperplasia by resisting the action of androgen.
Wang X; Zhu J; Yan H; Shi M; Zheng Q; Wang Y; Zhu Y; Miao L; Gao X
Eur J Pharmacol; 2021 Sep; 907():174251. PubMed ID: 34129879
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogenic activity of Riboflavin 5'-phosphate (FMN) in 22Rv1 and LNCaP human prostate cancer cell lines.
Choi YH; Kim J; Shin JY; Kang NG; Lee S
Eur J Pharmacol; 2022 Feb; 917():174743. PubMed ID: 34998793
[TBL] [Abstract][Full Text] [Related]
18. Primary prostate cancer cultures are models for androgen-independent transit amplifying cells.
Bühler P; Wolf P; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Freudenberg N; Elsässer-Beile U
Oncol Rep; 2010 Feb; 23(2):465-70. PubMed ID: 20043108
[TBL] [Abstract][Full Text] [Related]
19. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
20. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]